168 related articles for article (PubMed ID: 22880004)
21. Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.
Duan W; Ding H; Subler MA; Zhu WG; Zhang H; Stoner GD; Windle JJ; Otterson GA; Villalona-Calero MA
Oncogene; 2002 Nov; 21(51):7831-8. PubMed ID: 12420220
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional Signature Derived from Murine Tumor-Associated Macrophages Correlates with Poor Outcome in Breast Cancer Patients.
Tuit S; Salvagno C; Kapellos TS; Hau CS; Seep L; Oestreich M; Klee K; de Visser KE; Ulas T; Schultze JL
Cell Rep; 2019 Oct; 29(5):1221-1235.e5. PubMed ID: 31665635
[TBL] [Abstract][Full Text] [Related]
23. Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development.
Liu H; Kho AT; Kohane IS; Sun Y
PLoS Med; 2006 Jul; 3(7):e232. PubMed ID: 16800721
[TBL] [Abstract][Full Text] [Related]
24. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.
Girardini JE; Napoli M; Piazza S; Rustighi A; Marotta C; Radaelli E; Capaci V; Jordan L; Quinlan P; Thompson A; Mano M; Rosato A; Crook T; Scanziani E; Means AR; Lozano G; Schneider C; Del Sal G
Cancer Cell; 2011 Jul; 20(1):79-91. PubMed ID: 21741598
[TBL] [Abstract][Full Text] [Related]
25. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
26. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
[TBL] [Abstract][Full Text] [Related]
27. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
[TBL] [Abstract][Full Text] [Related]
28. The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.
Ramelow J; Brooks CD; Gao L; Almiman AA; Williams TM; Villalona-Calero MA; Duan W
BMC Cancer; 2020 Aug; 20(1):738. PubMed ID: 32770960
[TBL] [Abstract][Full Text] [Related]
29. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
30. Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1.
Fang L; Du WW; Lyu J; Dong J; Zhang C; Yang W; He A; Kwok YSS; Ma J; Wu N; Li F; Awan FM; He C; Yang BL; Peng C; MacKay HJ; Yee AJ; Yang BB
Cell Death Differ; 2018 Dec; 25(12):2195-2208. PubMed ID: 29795334
[TBL] [Abstract][Full Text] [Related]
31. p53 mutations in classic and pleomorphic invasive lobular carcinoma of the breast.
Ercan C; van Diest PJ; van der Ende B; Hinrichs J; Bult P; Buerger H; van der Wall E; Derksen PW
Cell Oncol (Dordr); 2012 Apr; 35(2):111-8. PubMed ID: 22354696
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: relationship to treatment outcome.
Gemba K; Ueoka H; Kiura K; Tabata M; Harada M
Lung Cancer; 2000 Jul; 29(1):23-31. PubMed ID: 10880844
[TBL] [Abstract][Full Text] [Related]
33. LKB1 modulates lung cancer differentiation and metastasis.
Ji H; Ramsey MR; Hayes DN; Fan C; McNamara K; Kozlowski P; Torrice C; Wu MC; Shimamura T; Perera SA; Liang MC; Cai D; Naumov GN; Bao L; Contreras CM; Li D; Chen L; Krishnamurthy J; Koivunen J; Chirieac LR; Padera RF; Bronson RT; Lindeman NI; Christiani DC; Lin X; Shapiro GI; Jänne PA; Johnson BE; Meyerson M; Kwiatkowski DJ; Castrillon DH; Bardeesy N; Sharpless NE; Wong KK
Nature; 2007 Aug; 448(7155):807-10. PubMed ID: 17676035
[TBL] [Abstract][Full Text] [Related]
34. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
35. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases.
Zhang Y; Xiong S; Liu B; Pant V; Celii F; Chau G; Elizondo-Fraire AC; Yang P; You MJ; El-Naggar AK; Navin NE; Lozano G
Nat Commun; 2018 Sep; 9(1):3953. PubMed ID: 30262850
[TBL] [Abstract][Full Text] [Related]
36. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
37. EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours.
Bornachea O; Santos M; Martínez-Cruz AB; García-Escudero R; Dueñas M; Costa C; Segrelles C; Lorz C; Buitrago A; Saiz-Ladera C; Agirre X; Grande T; Paradela B; Maraver A; Ariza JM; Prosper F; Serrano M; Sánchez-Céspedes M; Paramio JM
Sci Rep; 2012; 2():434. PubMed ID: 22666537
[TBL] [Abstract][Full Text] [Related]
38. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
Deeb KK; Michalowska AM; Yoon CY; Krummey SM; Hoenerhoff MJ; Kavanaugh C; Li MC; Demayo FJ; Linnoila I; Deng CX; Lee EY; Medina D; Shih JH; Green JE
Cancer Res; 2007 Sep; 67(17):8065-80. PubMed ID: 17804718
[TBL] [Abstract][Full Text] [Related]
39. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
[TBL] [Abstract][Full Text] [Related]
40. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.
Neskey DM; Osman AA; Ow TJ; Katsonis P; McDonald T; Hicks SC; Hsu TK; Pickering CR; Ward A; Patel A; Yordy JS; Skinner HD; Giri U; Sano D; Story MD; Beadle BM; El-Naggar AK; Kies MS; William WN; Caulin C; Frederick M; Kimmel M; Myers JN; Lichtarge O
Cancer Res; 2015 Apr; 75(7):1527-36. PubMed ID: 25634208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
